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Abstract
Background Antibiotic-loaded bone cement (ALBC) has
been used in serious cases of musculoskeletal tuberculosis,
but the type and amount of antibiotic that should be used in
ALBC have not been determined.
Questions/purposes We therefore determined the (1) elu-
tion characteristics and (2) antimycobacterial activity of
isoniazid- and rifampicin-loaded bone cement.
Methods A total of 240 elution samples of each of three
discs from 40 g bone cement mixed with one of eight dos-
ages: 1 g, 2 g, and 4 g isoniazid, 1 g, 2 g, and 4 g rifampicin,
and a combination of 1 + 1 g or 2 + 2 g of isoniazid and
rifampicin. The polymerization of rifampicin-loaded bone
cement was delayed to mean 122.5 ± 31.1 minutes. We
measured the quantity of isoniazid and rifampicin and the
antimycobacterial activity on Days 1, 3, 7, 14, and 30.
Results Isoniazid eluted in almost all the samples while rif-
ampicin was detected only on Day 1 with 2 g (0.7 ± 0.4 ug/
mL/day), and until Day 14 with 4 g (0.1 ± 0.0u g/mL/day).
Most of the samples containing isoniazid showed antimyco-
bacterial activity while the samples containing rifampicin
showed antimycobacterial activity only on Day 1 with 1 g
(0.52 ± 0.18 ug/mL), until Day 14 with 2 g (0.03 ± 0.00 ug/
mL), and until Day 30 with 4 g (1.84 ± 1.90 ug/mL).
Conclusion Rifampicin was unsuitable for ALBC
because of its delayed polymerization. Isoniazid eluted and
showed antimycobacterial activity for 30 days.
Clinical Relevance The data suggest isoniazid could be
considered for use in ALBC for musculoskeletal tuberculosis
if used with systemic treatment. For preventing resistance
and systemic toxicity, a combination with a second-line drug
and an in vivo study would be needed.
Introduction
Tuberculosis is still the most common cause of death from
infectious disease worldwide [44]. The incidence of tubercu-
losis gradually decreased through most of the 20th century [45],
but dramatically increased in the 1980 s and 1990 s, parallel to
the spread of AIDS [38]. Musculoskeletal tuberculosis accounts
for approximately 10% to 15% of all cases of tuberculosis in the
nonindustrialized world [32]. The most common site for skel-
etal involvement is the spine (50% of cases) [27], followed by
the pelvis (12%), hip and femur (10%), knee and tibia (10%),
and ribs (7%) [42, 45]. Bone tuberculosis has nonspecific
clinical symptoms and a long treatment period lasting for 6 to
18 months [38]; it is not easily cured and has recurrence rates
ranging from 0.0 % to 26.4 % [41]. If drug-resistant tuberculosis
occurs, extensive chemotherapy for as much as 2 years is
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required [38]. Musculoskeletal tuberculosis may be accompa-
nied by such serious complications as deformities resulting
from joint destruction [38].
Although antibiotic therapy remains the cornerstone of
treatment for musculoskeletal tuberculosis [31], surgical
treatment such as de´bridement and synovectomy [40, 46,
47], arthrodesis [6, 8, 21, 23], amputation [9, 18, 25, 35],
resection arthroplasty [4, 15, 17, 29, 37], or prosthetic joint
replacement [33] are required in serious cases. Several
studies have reported treating serious cases of musculo-
skeletal tuberculosis with antibiotic-loaded bone cement
(ALBC) [26, 28, 39] to control the infection and to sterilize
the joint [26]. These case series reported streptomycin- and
tobramycin-loaded bone cement treatment [26, 28, 39].
The selection of the proper antibiotic is important for
control of infection in ALBC treatment [11]. With pyo-
genic osteomyelitis, numerous studies have described the
selection of the appropriate type and amount of antibiotic
for ALBC treatment [1, 2, 5, 11, 13, 16] since ALBC was
introduced by Buchholz and Engelbrecht [7] in 1970.
However, there is limited information regarding ALBC for
treatment of musculoskeletal tuberculosis [26, 28, 39].
These case reports only document antibiotic-loaded bone
cements were used for control of tuberculous osteomyelitis
[26], but did not perform or cite systematically designed
studies to determine the type and amount of antibiotics for
ALBC. Anguita-Alonso et al. showed rifampicin can be
used to make beads [1], whereas two other studies [2, 13]
reported adding rifampicin with bone cement prevented
complete polymerization of the cement. Among the first-
line drugs for treatment of tuberculosis, including isonia-
zid, ethambutol, rifampicin, and pyrazinamide, we used
only isoniazid and rifampicin which are available for
intravenous administration and could be mixed with bone
cement aseptically [41].
We therefore conducted an in vitro study with isoniazid-
and rifampicin-loaded bone cement on the (1) elution
characteristics and (2) antibacterial activity.
Materials and Methods
We mixed eight different combinations of antibiotics with
40 g customized bone cement powder containing 1 g
gentamicin (CMW 3; DePuy, Warsaw, IN, USA) (Fig. 1).
The eight different combinations of antibiotics included
1 g, 2 g, or 4 g isoniazid (I3377; Sigma-Aldrich, St Louis,
MO, USA); 1 g, 2 g, or 4 g rifampicin (R3501; Sigma-
Aldrich); and a combination of 1 g + 1 g or 2 g + 2 g
isoniazid and rifampicin. The ALBC was made under
sterile conditions in the operating room. The powder
mixture was mixed by hand for 2 minutes after the liquid
monomer was added. For each of the eight combinations of
ALBC powder, three discs were made to measure the
elution characteristics and antibacterial activity. The discs
were cylinders made from premade molds and were
10 ± 0.8 mm in diameter and 50 ± 1.2 mm in height,
with a weight of 4.4 ± 0.26 g (Fig. 2). With all the ALBCs
containing rifampicin, including those with combined iso-
niazid and rifampicin, polymerization was delayed; a clay-
like texture persisted until the bone cement was hardened at
mean 122.5 ± 31.1 minutes. Each ALBC disc was
immersed in a 50-mL test tube that was protected from
light and contained 40 mL phosphate buffered saline
(PBS). The test tubes were kept at 37 C. The PBS was
replaced daily at a sterile bench. One millimeter of elution
sample (eluent) was taken for measurement of elution
characteristics and 1 mL for antimycobacterial activity on
Days 1, 3, 7, 14, and 30, just before exchanging the PBS. A
total of 240 samples (120 samples for elution characteris-
tics and 120 samples for antimycobacterial activity) were
obtained. All samples were frozen at 20 C until
measurement.
A liquid chromatography–mass spectrometry (LC/MS)
system was used to quantify the amount of antibiotic elu-
ent. The eluents were segregated with high-performance
liquid chromatography (HPLC)(Agilent 1100 series; Agi-
lent, Santa Clara, CA, USA) and detected with a mass
spectrometer (API3200; AB SCIEX, Framingham, MA,
USA). For the HPLC, 0.1% formic acid: acetonitrile (80:20
[v/v]) was used as the mobile phase, and Kinetex C18
(2.6 lm, 4.6 mm u x 50 mm; Phenomenex, Torrance, CA,
USA) was used as the column. We used the positive ion
mode and the multiple reaction monitoring mode for the
mass spectrograph.
To construct the calibration curve plot, the reference
standards of isoniazid and rifampicin were dissolved in
50% methanol to achieve a concentration of 10 lg/mL. We
then used this solution to create a reference solution with a
concentration of 0.1 to 50 lg/mL. The reference solution
was kept in cold storage. To analyze the specimens, each
specimen was centrifuged at 3000 rpm for 5 minutes. Then
0.1 L was injected into the LC/MS system and measured.
For each eluent, we measured antimycobacterial activity
against Mycobacterium tuberculosis (Mtb) H37Rv which
was modified from American Type Culture Collection
(ATCC) 25618 using the green fluorescent protein (GFP)
reporter microplate assay [12]. Mtb H37Rv-GFP was
grown in 10 mL of Middlebrook 7H9 broth (Difco, Sparks,
MD, USA) supplemented with 50 mg/L kanamycin, 0.2%
(v/v) glycerol (Sigma), 1.0 g Casitone (Difco) per liter,
10% (v/v) oleic acid, albumin, dextrose, and catalase
(OADC, Difco), and 0.05% (v/v) Tween1 80 (Sigma) until
its optical density at 600 nm reached 0.4. Twofold serial
dilutions of each eluent were made in 7H9 broth in the
microplates. The culture was diluted to 1:50 in 7H9 and
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was inoculated to yield 2 x 105 CFU/mL in plate wells. The
plates containing eluent dilutions and Mtb were incubated
at 37 C for 7 days, after which fluorescence was measured
in a Fluostar Optima (BMG Labtech GmbH, Ortenberg,
Germany) microplate fluorometer in the bottom-reading
mode with excitation at 485 nm and emission at 520 nm.
The minimal inhibitory concentration (MIC) was defined
as the lowest concentration of eluent that inhibited fluo-
rescence by 90% compared with the fluorescence of
bacteria-only wells. The MICs of isoniazid and rifampicin
were measured at the same time. The actual concentration
of each antibiotic in each eluent was calculated by com-
paring the MIC of each eluent with that of either isoniazid
or rifampicin. Antibacterial activity against Mtb was con-
sidered effective when the concentration of isoniazid was
greater than 0.031 lg/mL [10] and when the concentration
of rifampicin was greater than 0.016 lg/mL [10].
All the data are expressed as mean and SDs. Statistical
analyses were performed with the SPSS software for
Windows (version 20.0; SPSS, Chicago, IL, USA).
Results
Isoniazid was detected in almost all eluent samples
whereas rifampicin was only partly detected (Table 1).
Generally, the greater the concentration of the mixed
antibiotics the greater the concentration of the antibiotics in
the eluent and the lower the concentration became with
time (Table 1). However, rifampicin was not detected
except on Day 1 in the samples that contained 2 g rifam-
picin, and up to 2 weeks in the samples that contained 4 g
rifampicin. The same trend also was observed when iso-
niazid and rifampicin were mixed (Table 1). The elution
concentration of isoniazid decreased considerably to
approximately 20% at Day 3, but the concentration was
still 5% to 10% at Day 30 compared with Day 1. Like the
concentration of isoniazid, the concentration of rifampicin
decreased considerably after Day 1, even in the samples
that contained 4 g. The samples that contained 1 + 1 g and
2 + 2 g isoniazid showed a trend similar to that of the
Fig. 1 A chart shows the sche-
matic flow of this study.
ALBC = antibiotic-loaded bone
cement; PBS = phosphate buf-
fered saline.
Fig. 2 Antibiotic-loaded bone cement discs with 4 g isoniazid (upper
cylinder) and 4 g rifampicin (lower cylinder) are shown. The
rifampicin-loaded bone cement is bent after delayed polymerization.
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samples containing isoniazid alone, but rifampicin was not
detected (Table 1).
Most of the samples containing isoniazid showed anti-
mycobacterial activities while the samples containing
rifampicin only partly showed antimycobacterial activities
(Table 2). All the eluents containing isoniazid were
effective against Mtb. Rifampicin maintained its antimy-
cobacterial activity up to Day 30 in the samples containing
4 g rifampicin, but it maintained such activity only on Day
1 in the samples containing 1 g rifampicin, and up to
2 weeks in the samples containing 2 g rifampicin
(Table 2). In the samples containing isoniazid and rifam-
picin, antibacterial activity was present up to Day 30,
although it was unclear which drug was responsible for the
activity.
Discussion
ALBC treatment has been recommended to control serious
musculoskeletal tuberculosis infections [26, 28, 39].
However, the type and amount of antibiotics for ALBC for
treatment of musculoskeletal tuberculosis has not been
systematically studied with subsequent lack of adequate
guidelines. We therefore determined the (1) elution char-
acteristics and (2) antimycobacterial activity of isoniazid-
and rifampicin-loaded bone cement.
This study has some limitations. First, as it is an in vitro
study, it may not accurately reflect in vivo conditions. In
this study, PBS was exchanged daily to reproduce a
washout of the joint fluid, and elution fluid was collected
just before the exchange of PBS as a measure of the elution
concentration per day. Future studies such as those
involving animal testing are required to investigate the
concentration of antibiotics and their toxicity when oral
medications are concomitantly administered in real treat-
ments. Second, although a multidrug modality generally is
used to treat tuberculosis and can include the use of iso-
niazid, ethambutol, rifampicin, and pyrazinamide, we
included only isoniazid and rifampicin, which are available
in sterilized intravenous form. Furthermore, when rifam-
picin was used to create ALBC, the polymerization of the
bone cement was delayed, and thus we concluded rifam-
picin cannot be mixed with bone cement. Although
Anguita-Alonso et al. used rifampicin to make beads [1],
consistent with our study, others [2, 13] have reported the
combination of rifampicin with CMW prevents complete
polymerization of the cement (Table 3). As it was found
Table 1. Results of liquid chromatography–mass spectrometry (ug/mL/day)
Day Isoniazid Mean ± SD Rifampicin Mean ± SD Isoniazid + rifampicin Mean ± SD Mean ± SD
1 g 1 g 1 g + 1 g
Isoniazid Rifampicin
1* 2* 3* 1* 2* 3* 1* 2* 3* 1* 2* 3*
1 6.4 6.7 2.8 5.3 ± 2.2 ND ND ND ND 10.2 10.0 4.1 8.1 ± 3.5 ND ND ND ND
3 0.9 1.4 0.9 1.1 ± 0.3 ND ND ND ND 1.2 ND 1.2 1.2 ± 0.0 ND ND ND ND
7 1.6 0.0 1.6 1.1 ± 0.9 ND ND ND ND 0.9 0.7 0.4 0.7 ± 0.3 ND ND ND ND
14 1.2 1.2 1.4 1.3 ± 0.1 ND ND ND ND 0.2 0.3 0.2 0.2 ± 0.1 ND ND ND ND
30 0.6 0.4 0.4 0.5 ± 0.1 ND ND ND ND 0.1 0.1 0.1 0.1 ± 0.0 ND ND ND ND
2 g 2 g 2 g + 2 g
1 11.2 18.0 12.6 13.9 ± 3.6 0.3 0.6 1.1 0.7 ± 0.4 23.7 22.8 20.1 22.2 ± 1.9 ND 0.1 0.1 0.1 ± 0.0
3 1.9 2.8 2.3 2.3 ± 0.4 ND ND ND ND 4.0 3.8 2.4 3.4 ± 0.9 ND ND ND ND
7 2.9 2.8 2.8 2.8 ± 0.1 ND ND ND ND 2.2 1.9 1.4 1.8 ± 0.4 ND ND ND ND
14 1.1 2.1 2.4 1.9 ± 0.5 ND ND ND ND 4.4 1.4 1.2 2.3 ± 1.8 ND ND ND ND
30 1.5 0.6 0.7 0.9 ± 0.5 ND ND ND ND 0.6 0.3 0.4 0.4 ± 0.2 ND ND ND ND
4 g 4 g
1 30.9 22.5 21.3 24.9 ± 5.2 2.0 4.0 3.9 3.3 ± 1.1
3 3.6 3.8 3.9 3.8 ± 0.1 0.2 0.3 0.1 0.2 ± 0.1
7 4.7 5.0 5.2 5.0 ± 0.2 0.1 0.2 0.2 0.2 ± 0.1
14 3.6 0.1 2.9 2.2 ± 1.8 0.1 ND 0.1 0.1 ± 0.0
30 2.1 1.7 1.4 1.7 ± 0.3 ND ND ND ND
* Results from individual discs; ND = not detectable.
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that isoniazid can be mixed with bone cement, future
studies on second-line drugs such as moxifloxacin, kana-
mycin, or streptomycin are needed. Third, we tested only
one type of bacteria, Mycobacterium tuberculosis. Because
the rates of infection with nontuberculous mycobacteria
and multiresistant tuberculosis have been increasing [44,
45], studies on various strains are needed. Finally, variable
types of cement were not investigated in the current study,
and different types of cement could reveal different results
owing to their variable elution characteristics [1, 5, 11, 16,
24].
We found only isoniazid and not rifampicin showed
proper elution characteristics during the 30-day study
period. Even though the elution of isoniazid dramatically
decreased after Day 3, it persisted up to Day 30. To the best
of our knowledge, there has been no published study on
isoniazid-loaded bone cement. The elution characteristics
of isoniazid-loaded bone cement were superior to those of
rifampicin-loaded bone cement even ignoring the difficulty
of mixing rifampicin with bone cement.
Isoniazid showed antimycobacterial activity greater than
the MIC in every amount of isoniazid-loaded bone cement
for the entire study period and was superior to that for
rifampicin-loaded bone cement. Even though isoniazid
showed proper elution characteristics and antimycobacte-
rial activity for 30 days in our in vitro study, one should
consider using other second-line drugs together with iso-
niazid for several reasons. First, a minimum period for
treatment of musculoskeletal tuberculosis is longer than
30 days. The goal of ALBC is intensive administration of
antibiotics to the affected region in addition to systemic
chemotherapy, which is the cornerstone treatment of
musculoskeletal tuberculosis [38]. For an intensive effect
to an affected region, use of combined drugs is needed.
Second, isoniazid has the greatest bactericidal activity [22,
30], but it is the most common first-line agent to which
resistance is found in Mycobacterium tuberculosis [34].
When it is used for ALBC, especially, isoniazid in bone
cement could result in variable concentrations which can
result in underdosage and development of resistance [3].
Considering the reported high prevalence of multidrug-
resistant tuberculosis [43], additional studies are needed
with second-line agents that could be used with isoniazid
for ALBC. Third, isoniazid is widely distributed in body
fluids and tissues [20, 36] and could cause toxicity, espe-
cially to the liver [14, 19]. Even though the advantage of
ALBC is local administration of antibiotics, isoniazid could
increase the hepatotoxicity when combined with systemic
Table 2. Measurement of antimycobacterial activity of effusion sample (eluent) (ug/mL)
Day Isoniazid Mean ± SD Rifampicin Mean ± SD Isoniazid + rifampicin Mean ± SD
1 g 1 g 1 g + 1 g
1* 2* 3* 1* 2* 3* 1* 2* 3*
1 19.968 9.984 9.984 13.31 ± 5.76 0.625 0.624 0.313 0.52 ± 0.18 39.936 20.001 9.984 23.31 ± 15.25
3 0.624 1.248 0.624 0.83 ± 0.36 ND ND ND ND 0.624 ND 0.312 0.47 ± 0.22
7 1.284 ND 1.248 1.25 ± 0.00 ND ND ND ND 0.312 0.156 0.312 0.26 ± 0.09
14 0.500 1.000 1.000 0.83 ± 0.29 ND ND ND ND 0.250 0.062 0.125 0.15 ± 0.10
30 ND 0.500 0.250 0.38 ± 0.18 ND ND ND ND 0.063 0.063 0.063 0.06 ± 0.00
2 g 2 g 2 g + 2 g
1 39.936 19.968 19.968 26.62 ± 11.53 2.500 2.500 25.00 2.50 ± 0.0 39.936 79.872 79.872 66.56 ± 23.06
3 2.496 2.496 2.496 2.50 ± 0.00 0.250 0.250 0.016 0.17 ± 0.14 2.496 2.496 2.496 2.50 ± 0.00
7 2.496 2.496 2.496 2.50 ± 0.00 0.063 0.250 NC 0.16 ± 0.13 1.248 1.248 0.624 1.04 ± 0.36
14 2.000 2.000 2.000 2.00 ± 0.00 0.031 0.031 NC 0.03 ± 0.00 0.499 0.499 0.499 0.50 ± 0.00
30 ND 2.000 1.000 1.50 ± 0.71 ND ND ND ND 0.500 0.250 0.125 0.29 ± 0.19
4 g 4 g
1 79.872 79.872 39.936 66.56 ± 23.06 5.000 10.001 5.000 6.67 ± 2.89
3 4.992 4.992 2.496 4.16 ± 1.44 2.003 1.002 2.003 1.67 ± 0.58
7 4.992 4.992 4.992 4.99 ± 0.00 1.002 1.002 2.003 1.34 ± 0.58
14 4.000 8.000 7.992 6.66 ± 2.31 0.500 1.000 1.002 0.83 ± 0.29
30 4.006 2.000 8.013 4.67 ± 3.06 0.500 1.002 4.006 1.84 ± 1.90
Eluent was considered effective against Mycobacterium tuberculosis when the concentration was greater than 0.031 ug/mL for isoniazid or
greater than 0.016 ug/mL for rifampicin; * results from individual discs; ND = not detectable.
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treatment. Because the risk of hepatotoxicity increases with
age [20], use in elderly patients needs caution. We are fully
aware that for evaluation of toxicity and of the occurrence
of resistance, an in vivo study should be conducted, and
especially for resistance, second-line drug use with isoni-
azid should be considered.
We found rifampicin is unsuitable as an antibiotic for
bone cement owing to its delayed polymerization, but iso-
niazid eluted Mtb and showed antimycobacterial activity for
30 days. The findings suggest isoniazid can be considered
for use in ALBC if used with systemic treatment but this
would need to be confirmed with in vivo experiments. For
preventing resistance and considering its systemic toxicity,
isoniazid should be considered for second-line drug use.
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